Evidence map›Paper›PMID 38675976›Full record

ArticleViruses2024

U-CAN-seq: A Universal Competition Assay by Nanopore Sequencing.

Jennifer Diaz, John Sears, Che-Kang Chang, Jane Burdick, Isabella Law, Wes Sanders, Colton Linnertz, Paul Sylvester, Nathaniel Moorman, Martin T Ferris and 1 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jennifer DiazDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.ORCID 0000-0002-8067-0420
John SearsDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Che-Kang ChangDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Jane BurdickDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.ORCID 0009-0001-9719-8302
Isabella LawDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Wes SandersDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Colton LinnertzDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.ORCID 0000-0003-2969-8193
Paul SylvesterDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Nathaniel MoormanDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
Martin T FerrisDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.ORCID 0000-0003-1241-6268
Mark T HeiseDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA.
University of North Carolina at Chapel Hill · US

Funding

Research Project 1: Coronavirus antiviral lead development and combination testingU19AI171292 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, WILLSON, TIMOTHY M · 2022 to 2022
$65.5M
NIH HHS R21 AI128056NIH HHS U19 AI171292
6 · The paper itself

Abstract

RNA viruses quickly evolve subtle genotypic changes that can have major impacts on viral fitness and host range, with potential consequences for human health. It is therefore important to understand the evolutionary fitness of novel viral variants relative to well-studied genotypes of epidemic viruses. Competition assays are an effective and rigorous system with which to assess the relative fitness of viral genotypes. However, it is challenging to quickly and cheaply distinguish and quantify fitness differences between very similar viral genotypes. Here, we describe a protocol for using reverse transcription PCR in combination with commercial nanopore sequencing services to perform competition assays on untagged RNA viruses. Our assay, called the Universal Competition Assay by Nanopore Sequencing (U-CAN-seq), is relatively cheap and highly sensitive. We used a well-studied N24A mutation in the chikungunya virus (CHIKV) nsp3 gene to confirm that we could detect a competitive disadvantage using U-CAN-seq. We also used this approach to show that mutations to the CHIKV 5' conserved sequence element that disrupt sequence but not structure did not affect the fitness of CHIKV. However, similar mutations to an adjacent CHIKV stem loop (SL3) did cause a fitness disadvantage compared to wild-type CHIKV, suggesting that structure-independent, primary sequence determinants in this loop play an important role in CHIKV biology. Our novel findings illustrate the utility of the U-CAN-seq competition assay.

Indexed as

Chikungunya virusMutationNanopore SequencingAnimalsChikungunya FeverGenetic FitnessGenotypeHumansRNA, ViralRNA VirusesRNA, Viralalphaviruscompetition assaynanopore sequencingRNA virusviral fitness

Identifiers

PMID38675976
PMCPMC11054411
OpenAlexW4394953229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.